Here is the IC section on Arcontech - also covered SLP and MPAC7 Sep 2021 13:45
Arcontech unloved and materially under-rated
Flat revenue of £3m and pre-tax profit of £1.02m in 12 months to 30 June 2021.
Net cash up 8 per cent to £5.4m (40.6p a share).
Dividend raised 10 per cent to 2.75p a share.
High level of pent up demand with qualified list of prospective new customers across six countries.
Aim-traded financial software provider Arcontech (ARC:135p) delivered a resilient performance in its latest financial year despite the Covid-19 pandemic restricting customer contact due to remote working practices.
The company makes its money by providing software products and bespoke solutions for the collection, processing, distribution and presentation of time-sensitive financial markets data. Sales cycles are long and complex, which discourages clients from switching to another provider, so face-to-face meetings with key decision makers are key when pitching for a new contract. For instance, Arcontech needs to demonstrate: the potential cost savings of its solutions; how it can replicate the functionality of the clients’ existing products; and how it can deliver new benefits to minimise disruption. New contract awards are small initially and then scale up, so generating organic growth in future years.
Arcontech did manage to win new contracts in the 12-month trading period, one with a Tier One bank client, to add to its roll call of blue-chip clients which includes Barclays, JPMorgan, Morgan Stanley, and Bank of England. The small sales team has also been successful in strengthening the qualified pipeline of potential prospects, but Covid-19 restrictions have made converting the robust pipeline of opportunities difficult in the near-term, hence why the directors expect current year profits to be flat (or lower) as any pick up in revenue will not be fully reflected until the 2022/23 financial year.
The market reaction has been savage with Arcontech’s share price plunging below the 160p level at which I suggested buying at six months ago (‘Tap into a prodigious cash generator’, 28 February 2021). It’s a ridiculous overreaction. At the current price, the company has an enterprise valuation of £12.6m, or 12 times net profit, a low-ball valuation for a high margin (operating margin of 36 per cent), cash generative (free cash flow of £0.8m forecast in 2021/22) business that has strong defensive characteristics (recurring licence fees account for 93 per cent of annual revenue). Arcontech is also highly operationally geared given its relatively fixed cost base. Indeed, the incremental operating margin on new sales is around 60 per cent, so any contract wins have an accentuated impact on profits. Moreover, at the current valuation Arcontech is an obvious takeover target in a consolidating industry with peers trading on PE ratios of between 32 and 43 times. Recovery buy.